Medication info
Olostar Tablet 20/10mg (Olmesartan Medoxomil, Rosuvastatin)

Olostar Tablet 20/10mg (Olmesartan Medoxomil, Rosuvastatin)

Prescription medicationTabletOral
Ingredient · strength
Rosuvastatin Calcium›10.4mg / 1 tabletOlmesartan Medoxomil›20mg / 1 tablet
Manufacturer / importer
Daewoong Pharmaceutical Co., Ltd.
Appearance
White or yellowish round film-coated tablet
Packaging
30 tablets (10 tablets/PTP) × 3, 30 tablets/bottle
Approval status
Active

MFDS item code 201308278 · Approved 2013.07.18 · Insurance code 641605690

Summary

Main use
Treatment of hypertension, improvement of dyslipidemia, and inhibition of atherosclerosis progression and cardiovascular disease risk
Who takes it
Adults · Children
Adult dose
This medicine is for adults only. The dose should be individualized for each patient based on the effects and tolerability of each component, olmesartan medoxomil/rosuvastatin. ◆ Olmesartan medoxomil 1. Adults The recommended initial dose is 10mg once daily, with or without food. If blood pressure is not adequately controlled at this dose, increase to 20mg once daily. If additional blood pressure reduction is required, the dose may be increased to a maximum of 40mg once daily. The blood pressure-lowering effect appears within 2 weeks after starting treatment and reaches its maximum effect at approximately 8 weeks. If blood pressure is not controlled with this medicine alone, it may be coadministered with a thiazide diuretic such as hydrochlorothiazide. To improve adherence, it is recommended that the medicine be taken at the same time each day, if possible (e.g., in the morning). For patients who may have reduced intravascular effective blood volume (e.g., patients taking diuretics, particularly those with renal impairment), it is recommended to start treatment at a low dose while carefully monitoring their condition. 2. Older adults No dose adjustment is necessary when administering this medicine to older adults aged 65 years and older. No overall differences in efficacy or safety have been observed between older and younger patients; however, a more sensitive response in some older patients cannot be ruled out. 3. Patients with renal impairment The maximum dose in patients with mild or moderate renal impairment (creatinine clearance 30-60mL/min) is 20mg once daily. 4. Patients with hepatic impairment No dose adjustment is necessary in patients with mild hepatic impairment. The recommended initial dose in patients with moderate hepatic impairment is 10mg once daily, and the dose may be increased to a maximum of 20mg daily. Use is not recommended in patients with severe hepatic impairment because there is no experience of use in these patients. ◆ Rosuvastatin 1. Primary hypercholesterolemia (including heterozygous familial hypercholesterolemia, type IIa), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients receiving this medicine before and during treatment should follow a standard cholesterol-lowering diet and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which controls the condition in most patients. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response, and may be increased to a maximum of 20 milligrams daily. 2. Older adults No dose adjustment is necessary. 3. Patients with renal failure No dose adjustment is necessary in patients with mild or moderate renal failure. Do not administer to patients with severe renal failure. Exercise particular caution when administering 20mg of this medicine to patients with moderate renal failure. 4. Patients with hepatic failure No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience of administration in patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Ethnicity Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40 milligrams dose is contraindicated. 6. Patients predisposed to myopathy The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40 milligrams dose of this medicine is contraindicated in some of these patients. Patients taking olmesartan medoxomil and rosuvastatin concomitantly may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience.
Child dose
Safety and efficacy have not been established in children under 18 years of age.

Ingredients

Manufacturer
Daewoong Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of hypertension, improvement of dyslipidemia, and inhibition of atherosclerosis progression and cardiovascular disease risk

  • Essential hypertension
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed hyperlipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • primary dysbetalipoproteinemia
  • increased high-sensitivity C-reactive protein
  • hypertension
  • low HDL-cholesterol levels
  • smoking
  • family history of early coronary heart disease.
View approved original text

This medication is used for patients who need to take both olmesartan medoxomil and rosuvastatin. Olmesartan medoxomil is primarily used to treat essential hypertension. Meanwhile, rosuvastatin is effective for several lipid disorders including hypercholesterolemia and hyperlipidemia, particularly as an adjunctive treatment in cases where diet and exercise alone do not achieve adequate control. Additionally, rosuvastatin helps delay the progression of atherosclerosis and reduce the risk of cardiovascular diseases. It particularly plays a role in reducing the risks of issues that may occur after myocardial infarction, stroke, or vascular revascularization. Therefore, this medication is useful in improving the health status of patients with both hypertension and lipid disorders.

How to take

Adult dose

This medicine is for adults only. The dose should be individualized for each patient based on the effects and tolerability of each component, olmesartan medoxomil/rosuvastatin. ◆ Olmesartan medoxomil 1. Adults The recommended initial dose is 10mg once daily, with or without food. If blood pressure is not adequately controlled at this dose, increase to 20mg once daily. If additional blood pressure reduction is required, the dose may be increased to a maximum of 40mg once daily. The blood pressure-lowering effect appears within 2 weeks after starting treatment and reaches its maximum effect at approximately 8 weeks. If blood pressure is not controlled with this medicine alone, it may be coadministered with a thiazide diuretic such as hydrochlorothiazide. To improve adherence, it is recommended that the medicine be taken at the same time each day, if possible (e.g., in the morning). For patients who may have reduced intravascular effective blood volume (e.g., patients taking diuretics, particularly those with renal impairment), it is recommended to start treatment at a low dose while carefully monitoring their condition. 2. Older adults No dose adjustment is necessary when administering this medicine to older adults aged 65 years and older. No overall differences in efficacy or safety have been observed between older and younger patients; however, a more sensitive response in some older patients cannot be ruled out. 3. Patients with renal impairment The maximum dose in patients with mild or moderate renal impairment (creatinine clearance 30-60mL/min) is 20mg once daily. 4. Patients with hepatic impairment No dose adjustment is necessary in patients with mild hepatic impairment. The recommended initial dose in patients with moderate hepatic impairment is 10mg once daily, and the dose may be increased to a maximum of 20mg daily. Use is not recommended in patients with severe hepatic impairment because there is no experience of use in these patients. ◆ Rosuvastatin 1. Primary hypercholesterolemia (including heterozygous familial hypercholesterolemia, type IIa), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients receiving this medicine before and during treatment should follow a standard cholesterol-lowering diet and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which controls the condition in most patients. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response, and may be increased to a maximum of 20 milligrams daily. 2. Older adults No dose adjustment is necessary. 3. Patients with renal failure No dose adjustment is necessary in patients with mild or moderate renal failure. Do not administer to patients with severe renal failure. Exercise particular caution when administering 20mg of this medicine to patients with moderate renal failure. 4. Patients with hepatic failure No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience of administration in patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Ethnicity Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40 milligrams dose is contraindicated. 6. Patients predisposed to myopathy The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40 milligrams dose of this medicine is contraindicated in some of these patients. Patients taking olmesartan medoxomil and rosuvastatin concomitantly may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience.

Child dose

Safety and efficacy have not been established in children under 18 years of age.

Precautions

This medication can cause serious harm to the fetus and newborn if taken during the second and third trimesters of pregnancy, so it should be discontinued immediately upon confirmation of pregnancy. It should not be used in individuals who have an allergy to any of its components, in pregnant or breastfeeding women, or in fertile women not using appropriate contraception. Patients with severely impaired kidney function or those undergoing kidney dialysis, patients with severe liver dysfunction, patients with bile duct obstruction, and those with certain muscle diseases should not take this medication. Particularly, caution is required for patients taking high doses of rosuvastatin (40mg) who have a history of kidney function impairment, hypothyroidism, or genetic muscle disorders due to increased risk of muscle damage. This medication contains lactose, so it should not be administered to patients with lactose intolerance or related genetic disorders. Patients with reduced blood volume or low sodium levels may experience hypotension at the beginning of treatment, so their condition should be monitored carefully. Patients with impaired kidney function or kidney transplant recipients should have their kidney function and electrolyte status checked regularly through blood tests. There is a risk of hyperkalemia, so especially for patients with heart failure or kidney disease, blood potassium levels should be monitored closely. Dizziness may occur during treatment, so caution should be exercised when driving or operating dangerous machinery. If symptoms such as liver dysfunction or muscle pain appear, patients should notify healthcare professionals immediately, and liver function tests and muscle enzyme tests should be performed if necessary. This medication can interact with other drugs, so if patients are taking other medications, they must inform healthcare providers. The safety and efficacy of this medication have not been established in children and adolescents under 18 years old, so its use is not recommended. Elderly patients may have increased plasma concentrations of this medication, so dose adjustments and caution are necessary. In case of overdose, symptoms such as blood pressure reduction and cardiac arrhythmias may appear, requiring immediate medical attention.

Side effects

Increased ALT, increased AST, elevated blood creatinine, decreased creatinine clearance, headache, dizziness, sensory impairment, neuromuscular disease, drowsiness, gastroesophageal reflux disease, constipation, dental caries, indigestion, gastric ulcer, gastritis, gastroenteritis, musculoskeletal stiffness, atrial fibrillation, hypoglycemia, chest pain, tooth extraction, chest discomfort, peripheral edema, vertigo, abdominal pain, nausea, palpitations, hypercholesterolemia, hyperlipidemia, hyperuricemia, arthralgia, arthritis, myalgia, rash, facial edema, asthenia, angioedema, anaphylactic reaction, vomiting, chronic malabsorption syndrome, intestinal vascular edema, rhabdomyolysis, hyperkalemia, acute renal failure, hair loss, pruritus, urticaria, autoimmune hepatitis, dizziness (including positional vertigo), palpitations, increased blood pressure, low back pain, elevated serum creatinine, diarrhea, cough, nasal hemorrhage, upper respiratory tract infection, asthma, hypersensitivity reactions including angioedema, diabetes, pancreatitis, pruritus, rash and urticaria, myalgia, myopathy, rhabdomyolysis, asthenia, polyneuropathy, amnesia, peripheral neuropathy, dyspnea, thrombocytopenia, jaundice, hepatitis, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms, lupus-like syndrome, muscle tear, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, severe myasthenia, ophthalmoplegia

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to air and moisture, so it should be stored in a sealed container. The recommended storage temperature is room temperature between 1 to 30 degrees. This will help maintain the medication's efficacy for a longer period.

Appearance and packaging

Appearance

White or yellowish round film-coated tablet

Package unit

30 tablets (10 tablets/PTP) × 3, 30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.